Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis
Open accessThe DOI matches its Crossref record; 39 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Interventional diagnostic and therapeutic procedures requiring intravascular iodinated contrast steadily increase patient exposure to the risks of contrast-induced acute kidney injury (CIAKI), which is associated with death, nonfatal cardiovascular events, and prolonged hospitalization. The aim of this study was to investigate the efficacy of pharmacological and non-pharmacological treatments for CIAKI prevention in patients undergoing cardiovascular invasive procedures with iodinated contrast. METHODS AND FINDINGS: MEDLINE, Google Scholar, EMBASE and Cochrane databases as well as abstracts and presentations from major cardiovascular and nephrology meetings were searched, up to 22 April 2016. Eligible studies were randomized trials comparing strategies to prevent CIAKI (alone or in combination) when added to saline versus each other, saline, placebo, or no treatment in patients undergoing cardiovascular invasive procedures with administration of iodinated contrast. Two reviewers independently extracted trial-level data including number of patients, duration of follow-up, and outcomes. Eighteen strategies aimed at CIAKI prevention were identified. The primary outcome was the occurrence of CIAKI. Secondary outcomes were mortality, myocardial infarction, dialysis and heart failure. The data were pooled using network meta-analysis. Treatment estimates were calculated as odds ratios (ORs) with 95% credible intervals (CrI). 147 RCTs involving 33,463 patients were eligible. Saline plus N-acetylcysteine (OR 0.72, 95%CrI 0.57-0.88), ascorbic acid (0.59, 0.34-0.95), sodium bicarbonate plus N-acetylcysteine (0.59, 0.36-0.89), probucol (0.42, 0.15-0.91), methylxanthines (0.39, 0.20-0.66), statin (0.36, 0.21-0.59), device-guided matched hydration (0.35, 0.12-0.79), prostaglandins (0.26, 0.08-0.62) and trimetazidine (0.26, 0.09-0.59) were associated with lower odds of CIAKI compared to saline. Methylxanthines (0.12, 0.01-0.94) or left ventricular end-diastolic pressure-guided hydration (0.09, 0.01-0.59) were associated with lower mortality compared to saline. CONCLUSIONS: Currently recommended treatment with saline as the only measure to prevent CIAKI during cardiovascular procedures may not represent the optimal strategy. Vasodilators, when added to saline, may significantly reduce the odds of CIAKI following cardiovascular procedures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite the acknowledged clinical benefits of lowering LDLC in patients with ACS [436], attainment of LDL-C target values remains suboptimal in this very high-risk setting [437].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [437]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269 · cited 1×
“We registered the study protocol with PROSPERO (CRD42015016488) and conducted and reported this review using the Preferred Reporting Items for Systematic Reviews and Metaanalyses (PRISMA) extension statement for reporting systematic reviews incorporating network meta-analyses of health care interventions (S1 File)[6].”
Method2018 ESC/EACTS guidelines on myocardial revascularization
Neumann, F.-J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., Byrne, R. A., Collet, J.-P., Falk, V., Head, S. J., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy394 · Cited by 7,167
Self-citationUchino, S. (2005) · JAMA · doi:10.1001/jama.294.7.813 · Cited by 4,176 · cited 1×
“The underlying mechanisms leading to harmful effects of renal replacement therapy are possibly multiple; hypotension and myocardial stunning may correlate with loss of residual renal function[31,32]; blood contact with the dialysis membrane may promote a pro-inflammatory systemic response which may in itself lead to a…”
BackgroundWriting Committee Members, Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31823ba622 · Cited by 3,289
Checking consistency in mixed treatment comparison meta-analysis
Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010) · Statistics in Medicine · doi:10.1002/sim.3767 · Cited by 2,521 · cited 1×
“We evaluated evidence of inconsistency in the network, defined as difference in treatment estimates derived from direct and indirect treatment comparisons, using the node splitting method and the corresponding Bayesian pvalue, which determines the statistical agreement between direct and indirect evidence for each spl…”
Self-citationCombination of direct and indirect evidence in mixed treatment comparisons
Lu, G., & Ades, A. E. (2004) · Statistics in Medicine · doi:10.1002/sim.1875 · Cited by 2,166 · cited 1×
“Network meta-analyses compare different treatments within a connected analytical network [8], integrating data from direct and indirect treatment comparisons whilst maintaining the randomisation design[9].”
Method2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., Hollenberg, S. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.007 · Cited by 2,164
Plasma aldosterone regulation in anephric man
Walker, W. G., & Cooke, C. R. (1973) · Kidney International · doi:10.1038/ki.1973.1 · Cited by 1,841
Bayesian Approaches to Clinical Trials and Health‐Care Evaluation
Spiegelhalter, D. J., Abrams, K. R., & Myles, J. P. (2003) · Wiley eBooks · doi:10.1002/0470092602 · Cited by 1,673
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Protective Role for Antioxidants in Acute Kidney Disease
Dennis, J., & Witting, P. (2017) · Nutrients · doi:10.3390/nu9070718 · Cited by 291
“Although some studies included patients with existing renal dysfunction, recent meta-analyses show overall benefit of vitamin C in preventing CI-AKI compared to placebo or normal saline hydration [142,143].”
ResultContemporary Management of Severe Acute Kidney Injury and Refractory Cardiorenal Syndrome
Jentzer, J. C., Bihorac, A., Brusca, S. B., Rio‐Pertuz, G. D., KASHANI, K. B., Kazory, A., Kellum, J. A., Mao, M. A., Moriyama, B., Morrow, D. A., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.06.070 · Cited by 155
Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter?
Rossini, E., Biscetti, F., Rando, M. M., Nardella, E., Cecchini, A. L., Nicolazzi, M. A., Covino, M., Gasbarrini, A., Massetti, M., & Flex, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169326 · Cited by 31
“In addition, statin pretreatment has also been shown to reduce the risk of contrast-induced acute kidney injury after coronary angiography or interventional therapy [27].”
BackgroundGreco, A., Finocchiaro, S., Angiolillo, D. J., & Capodanno, D. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2171788 · Cited by 23
Contrast-Induced Nephropathy: Update on the Use of Crystalloids and Pharmacological Measures
Patschan, D., Buschmann, I. R., & Ritter, O. (2018) · International Journal of Nephrology · doi:10.1155/2018/5727309 · Cited by 21
Moroni, F., Baldetti, L., Kabali, C., Briguori, C., Maioli, M., Toso, A., Brilakis, E. S., Gurm, H. S., Bagur, R., & Azzalini, L. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021342 · Cited by 21
“42”
Brockmeyer, M., Wolff, G., Krieger, T., Lin, Y., Karathanos, A., Afzal, S., Zeus, T., Westenfeld, R., Polzin, A., Heinen, Y., et al. (2019) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2019.1585643 · Cited by 21
“It may be associated with mortality and major adverse events in cardiac procedures [45], but comparable data from large-scale clinical trials in LAAO are lacking.”
BackgroundSelf-citationXu, Y., Zheng, X., Liang, B., Gao, J., & Gu, Z. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0274-3 · Cited by 18
“To the best of our knowledge, two recent systematic reviews maintained that vitamin C afforded effective nephroprotection against CI-AKI [9, 10].”
BackgroundCommunity Health Care Quality Standards to Prevent Acute Kidney Injury and Its Consequences
Silver, S. A., Nadim, M. K., O'Donoghue, D. J., Wilson, F. P., Kellum, J. A., Mehta, R. L., Ronco, C., KASHANI, K. B., Rosner, M. H., Haase, M., et al. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.10.038 · Cited by 17
Ma, X., Li, X., Jiao, Z., & Zhang, Y. (2017) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12316 · Cited by 14
Bellos, I., Iliopoulos, D., & Perrea, D. N. (2019) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000663 · Cited by 11
Fu, N., Yang, S., Zhang, J., Zhāng, P., Liang, M., Cong, H., Lin, W., Tian, F., & Lu, C. (2017) · International Urology and Nephrology · doi:10.1007/s11255-017-1718-4 · Cited by 9
“Some studies report that probucol plays a prophylactic role in the development of CIN [11, 12], but most of these studies were single-center studies using small sample sizes.”
ResultPharmacologic Prophylaxis of Contrast-Induced Nephropathy
Toso, A., Leoncini, M., Maioli, M., & Bellandi, F. (2020) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2020.02.006 · Cited by 9
Wang, Y., Shi, Y., Xu, X., Ge, W., Yang, S., & Lu, C. (2019) · Medicine · doi:10.1097/md.0000000000016049 · Cited by 8
Trimetazidine in Cardiovascular Disease and Beyond: A Comprehensive Review
Goel, H., Roma, N., Morgan, M., Arora, R., Sreejith, N., Goyal, D., & Nadar, S. K. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00724-1 · Cited by 7
Fernandez-Berges, D. J., Degano, I. R., González-Fernández, R., Subirana, I., Vila, J., Jiménez-Navarro, M. F., Pérez-Fernández, S., Roqué, M., Bayés‐Genís, A., Fernández‐Avilés, F., et al. (2020) · Open Heart · doi:10.1136/openhrt-2019-001169 · Cited by 7
Kalogirou, T. E., Meditskou, S., Davidopoulou, S., Savvas, I., Pitoulias, A. G., & Pitoulias, G. A. (2019) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-019-02304-8 · Cited by 7
Zeid, A. S., & Sayed, S. S. E. D. (2020) · Saudi Journal of Kidney Diseases and Transplantation · doi:10.4103/1319-2442.301203 · Cited by 6
Parco, C., Brockmeyer, M., Kosejian, L., Quade, J., Tröstler, J., Bader, S., Lin, Y., Sokolowski, A., Hoss, A., Heinen, Y., et al. (2021) · Journal of Nephrology · doi:10.1007/s40620-021-01124-9 · Cited by 8
Self-citationRoumeliotis, S. K., Neofytou, I. E., Kantartzi, K. M., Georgianos, P. I., & Liakopoulos, V. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673298815240605071808 · Cited by 5
Михайлович, М. Е., Vyalkina, Y. A., & Шалаев, С. В. (2022) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2022-08-10 · Cited by 1
Ibrahim, A. A. A., Tabassum, S., Abuelazm, M., Amin, A. M., Rakab, M. S., Rifai, M. K., Manasrah, A., Mahmoud, A., Emara, A. G., Abdelazeem, B., et al. (2024) · International Urology and Nephrology · doi:10.1007/s11255-024-04261-9 · Cited by 1
“Though peripro-cedural hydration is a widely used prophylactic approach against CIN, [8] there is currently no effective strategy to treat CIN.”
Taylor, J., Patel, S., Gaitonde, K., Greene, K. L., Liao, J. C., McWilliams, G. W., Sawyer, M., Schroeck, F. R., Alrabaa, A., Saffati, G., et al. (2024) · Current Oncology · doi:10.3390/curroncol31110493 · Cited by 2
“The risk of contrast-induced kidney injury can be as high as 25% in elderly patients with a combination of chronic kidney disease, diabetes, heart failure, and exposure to nephrotoxic drugs [24].”
Koziolova, N. A., Колегова, И. И., & Суровцева, М. В. (2018) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2018-1-57-62 · Cited by 1
Preventing EVAR Associated Acute Kidney Injury: The Optimal Strategy Remains Elusive
Boyle, J. R. (2018) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2018.02.013 · Cited by 1
Lipid lowering therapy in particular patient populations
Güngör, B. (2020) · Updates in Cardiology · doi:10.5543/ucard.2019.09797 · Cited by 1
“Yüksek doz statin tedavisi kontrast ilişkili nefropati riskinde azalma sağlayabilir.[8]”
Nicorandil for CIN Prevention — A Hope or Hype?
Ghaffar, Y. A., & Daggubati, R. B. (2020) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2020.07.006
Roy, D., Pande, S. D., Aw, T. C., Hausenloy, D. J., Walsh, S. R., Morris, J., & Tang, T. Y. (2019) · Research Square · doi:10.21203/rs.2.14116/v2
“There is still discrepancy in literature as to which preventative strategy is best [19].”
BackgroundRoy, D., Pande, S. D., Aw, T. C., Hausenloy, D. J., Walsh, S. R., Morris, J., & Tang, T. Y. (2019) · Research Square · doi:10.21203/rs.2.14116/v1
Roy, D., Pande, S. D., Aw, T. C., Hausenloy, D. J., Walsh, S. R., Morris, J., & Tang, T. (2019) · doi:10.21203/rs.2.14116/v3
Roy, D., Pande, S. D., Aw, T. C., Hausenloy, D. J., Walsh, S. R., Morris, J., & Tang, T. (2019) · doi:10.21203/rs.2.14116/v4
Jones, J. E., Tuite, P. K., & Guttendorf, J. (2023) · Dimensions of Critical Care Nursing · doi:10.1097/dcc.0000000000000599
Treatment of dyslipidemia in acute coronary syndrome
Yadav, S., & Sawhney, J. P. S. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.01.011 · Cited by 3
Vitamin E for the Prevention of Contrast-Induced Nephropathy: A Systematic Review and Meta-Analysis
Awaji, A. A., Bakhamees, B. H., Alalshaikh, N. K., Albelwi, N. M., Al-Zahrani, M. M., Alshammari, K. F., Almutairi, S. D., Siraj, I. M., Aljaber, T. N., Alnajdi, R. S., et al. (2024) · Cureus · doi:10.7759/cureus.63256
Yamashita, S., & Masuda, D. (2025) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2025.16
Zavaleta-Monestel, E., Mora-Jiménez, J., Cruz-Mora, K., Arguedas‐Chacón, S., Herrera-Jiménez, L. G., Castro-Gamboa, J. A., & Chaverri‐Fernández, J. M. (2026) · Kidney and Dialysis · doi:10.3390/kidneydial6030054
“Other proposed interventions—including furosemide, mannitol, fenoldopam, dopamine, theophylline, and ascorbic acid—have not demonstrated reproducible clinical benefit or may introduce additional risks [33,34,37–43].”
Metadata
- Authors
- Navarese, E. P., Gurbel, P. A., Andreotti, F., Kołodziejczak, M. M., Palmer, S. C., Dias, S., Buffon, A., Kubica, J., Kowalewski, M., Jadczyk, T., Laskiewicz, M., Jędrzejek, M., Brockmeyer, M., Airoldi, F., Ruospo, M., De Servi, S., Wojakowski, W., O’ Connor, C., & Strippoli, G. F. M.
- Affiliations
- MultiMedica (IT)
- Inova Fairfax Hospital (US)
- Nicolaus Copernicus University (PL)
- University of Otago (NZ)
- University of Bristol (GB)
- Antoni Jurasz University Hospital (PL)
- Medical University of Silesia (PL)
- Heinrich Heine University Düsseldorf (DE)
- The University of Sydney (AU)
- Corresponding author
- Navarese, Eliano P.
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-02-02
- Volume
- 12
- Issue
- 2
- Pages
- e0168726
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5289438
- OpenAlex
- W2584407743
- Cited by
- 38
- References
- 41
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 5 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 6 · 2019: 11 · 2018: 4 · 2017: 3
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Bristol Research (University of Bristol) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
- Explore Bristol Research (submittedVersion, cc-by)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- University of Otago
- CSL Behring
- Regeneron Pharmaceuticals
- National Institutes of Health
- Medical Research Council (MR/M005232/1)
- National Heart, Lung, and Blood Institute
- Duke Clinical Research Institute
- Daiichi Sankyo Europe
- Actelion Pharmaceuticals
- Topics
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Chemotherapy-induced organ toxicity mitigation
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- contrast-induced nephropathy, acute kidney injury prevention, iodinated contrast media, cardiovascular procedures, N-acetylcysteine, vitamin C, sodium bicarbonate, probucol, methylxanthines, statins, prostaglandins, trimetazidine, myocardial infarction, mortality, dialysis, heart failure
- MeSH terms
- Contrast Media, Diagnostic Techniques, Cardiovascular, Humans, Kidney Function Tests, Vasodilator Agents, Radiography, Interventional, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.